6.
Ulas E, Hashemi S, Houda I, Kaynak A, Veltman J, Fransen M
. Predictive Value of Combined Positive Score and Tumor Proportion Score for Immunotherapy Response in Advanced NSCLC. JTO Clin Res Rep. 2023; 4(9):100532.
PMC: 10480627.
DOI: 10.1016/j.jtocrr.2023.100532.
View
7.
Orlhac F, Soussan M, Maisonobe J, Garcia C, Vanderlinden B, Buvat I
. Tumor texture analysis in 18F-FDG PET: relationships between texture parameters, histogram indices, standardized uptake values, metabolic volumes, and total lesion glycolysis. J Nucl Med. 2014; 55(3):414-22.
DOI: 10.2967/jnumed.113.129858.
View
8.
Lee J, Lee S
. Radiomics in Oncological PET/CT: Clinical Applications. Nucl Med Mol Imaging. 2018; 52(3):170-189.
PMC: 5995782.
DOI: 10.1007/s13139-017-0500-y.
View
9.
Lambin P, Rios-Velazquez E, Leijenaar R, Carvalho S, van Stiphout R, Granton P
. Radiomics: extracting more information from medical images using advanced feature analysis. Eur J Cancer. 2012; 48(4):441-6.
PMC: 4533986.
DOI: 10.1016/j.ejca.2011.11.036.
View
10.
Nioche C, Orlhac F, Boughdad S, Reuze S, Goya-Outi J, Robert C
. LIFEx: A Freeware for Radiomic Feature Calculation in Multimodality Imaging to Accelerate Advances in the Characterization of Tumor Heterogeneity. Cancer Res. 2018; 78(16):4786-4789.
DOI: 10.1158/0008-5472.CAN-18-0125.
View
11.
Jreige M, Letovanec I, Chaba K, Renaud S, Rusakiewicz S, Cristina V
. F-FDG PET metabolic-to-morphological volume ratio predicts PD-L1 tumour expression and response to PD-1 blockade in non-small-cell lung cancer. Eur J Nucl Med Mol Imaging. 2019; 46(9):1859-1868.
DOI: 10.1007/s00259-019-04348-x.
View
12.
Wang D, Qiu B, Liu Q, Xia L, Liu S, Zheng C
. Patlak-Ki derived from ultra-high sensitivity dynamic total body [F]FDG PET/CT correlates with the response to induction immuno-chemotherapy in locally advanced non-small cell lung cancer patients. Eur J Nucl Med Mol Imaging. 2023; 50(11):3400-3413.
DOI: 10.1007/s00259-023-06298-x.
View
13.
Erber R, Stohr R, Herlein S, Giedl C, Rieker R, Fuchs F
. Comparison of mRNA Expression Measured with the CheckPoint Typer® Assay with PD-L1 Protein Expression Assessed with Immunohistochemistry in Non-small Cell Lung Cancer. Anticancer Res. 2017; 37(12):6771-6778.
DOI: 10.21873/anticanres.12137.
View
14.
Bauml J, Seiwert T, Pfister D, Worden F, Liu S, Gilbert J
. Pembrolizumab for Platinum- and Cetuximab-Refractory Head and Neck Cancer: Results From a Single-Arm, Phase II Study. J Clin Oncol. 2017; 35(14):1542-1549.
PMC: 5946724.
DOI: 10.1200/JCO.2016.70.1524.
View
15.
Mok T, Wu Y, Kudaba I, Kowalski D, Cho B, Turna H
. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial. Lancet. 2019; 393(10183):1819-1830.
DOI: 10.1016/S0140-6736(18)32409-7.
View
16.
Takada K, Toyokawa G, Okamoto T, Baba S, Kozuma Y, Matsubara T
. Metabolic characteristics of programmed cell death-ligand 1-expressing lung cancer on F-fluorodeoxyglucose positron emission tomography/computed tomography. Cancer Med. 2017; 6(11):2552-2561.
PMC: 5673920.
DOI: 10.1002/cam4.1215.
View
17.
Borghaei H, Langer C, Paz-Ares L, Rodriguez-Abreu D, Halmos B, Garassino M
. Pembrolizumab plus chemotherapy versus chemotherapy alone in patients with advanced non-small cell lung cancer without tumor PD-L1 expression: A pooled analysis of 3 randomized controlled trials. Cancer. 2020; 126(22):4867-4877.
PMC: 7692929.
DOI: 10.1002/cncr.33142.
View
18.
Kim B, Kang J, Jun S, Kim H, Pak K, Kim G
. Association between immunotherapy biomarkers and glucose metabolism from F-18 FDG PET. Eur Rev Med Pharmacol Sci. 2020; 24(16):8288-8295.
DOI: 10.26355/eurrev_202008_22625.
View
19.
McGranahan N, Swanton C
. Clonal Heterogeneity and Tumor Evolution: Past, Present, and the Future. Cell. 2017; 168(4):613-628.
DOI: 10.1016/j.cell.2017.01.018.
View
20.
Sauter A, Schwenzer N, Divine M, Pichler B, Pfannenberg C
. Image-derived biomarkers and multimodal imaging strategies for lung cancer management. Eur J Nucl Med Mol Imaging. 2015; 42(4):634-43.
DOI: 10.1007/s00259-014-2974-5.
View